时隔一年多后，派林生物又在筹划控制权变更

Group 1 - The core point of the news is that Pailin Bio is undergoing a change in control, with the major shareholder, Qiongcheng Shengbang Yinghao Investment Partnership, notifying the company about the planned change, which is still in the planning stage and has significant uncertainty [1][2] - Pailin Bio is a blood product company with a total of 11 blood product varieties, ranking among the top in the industry [2] - The last change in control occurred in October 2023, when Shengbang Yinghao became the controlling shareholder, and the actual controller changed to the State-owned Assets Supervision and Administration Commission of the Shaanxi Provincial People's Government [2] Group 2 - In the first quarter of 2025, Pailin Bio reported a revenue of 375 million and a net profit attributable to shareholders of 89.09 million, with year-on-year declines of 14% and 26.95% respectively [3] - The decline in performance is attributed to the inability to meet operational development needs due to continuous growth in plasma collection, and the expansion of production capacity at its subsidiaries has been affected by the suspension of operations at the second phase of production at Pailisifike [3] - Pailin Bio has been ordered to rectify inaccurate information disclosure due to internal deficiencies in business and contract management by the Shanxi Securities Regulatory Bureau [3]